Growblox Sciences Announces Launch of New Corporate Website
May 11 2015 - 12:21PM
Growblox Sciences Inc. (OTCQB:GBLX) ("Growblox" or the "Company"),
a biopharmaceutical research and development company with
state-of-the-art technologies in plant biology and cultivation
designed to produce consistent medicinal cannabis, announced today
the launch of its new corporate website.
"We have navigated many obstacles in the process of refining our
vision and gathering a complete understanding of the medicinal
cannabis landscape. We believe that our evolution has enabled a
compelling message to emerge very clearly, which we are pleased to
present on our new corporate site; Growblox is here to cultivate an
industry, not just a plant," said CEO Craig Ellins.
The corporate site http://www.Growblox.com provides extensive
content regarding the Company's position in the market and is
intended to highlight three (3) operating divisions of the Company:
GB Sciences, GB Solutions and GB Products.
- GB Sciences: Handles all
regulatory, compliance, clinical trials, product claim validation
and new drug discovery. Led by Growblox Sciences' Chief
Science Officer, Dr. Andrea Small-Howard, this division is expected
to collaborate with academic and institutional partners, such as
the University of Puerto Rico and various clinical research
organizations, in order to create a novel cannabinoid therapy
pipeline.
- GB Solutions: Focuses on supply
chain and logistics and will be overseen by Puerto Rican business
leader Cesar Cordero-Kruger, as head of our majority owned
subsidiary Growblox Sciences Puerto Rico, LLC. Under his
leadership the GB Solutions division will be responsible for all
engineering, industrial design and systems validation including the
commercialization of company's propriety cultivation system known
as the GrowBLOX™ Technology Suite.
- GB Products: Expected to be
formally launched by the end of Q3
2015. Lead by Growblox Sciences' Co-founder
Lucas Marin, this division will be taking over product design,
marketing and distribution of consumer ready cannabinoid therapies
and specialized products.
The website also features the Company's focus on scientific
validation for the medical cannabis industry, supply chain
solutions designed to set a path for national distribution and the
strong brand identities that will lead the future of cannabinoid
therapies. This is the first step of the new communication strategy
that the biotechnology company will deploy to target potential
partners and investors in the fast growing medical cannabis
space.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (OTCQB:GBLX) is a biopharmaceutical
research and development company focused on creating safe,
standardized pharmaceutical-grade cannabis-based therapies that
target a variety of medical conditions. The Company is leading
pioneering technology and industry processes, with a "big"
data-driven clinical research and development loop ability to bring
relief to patients in communities across the country. Through
our GBSPR subsidiary, we are developing and distributing our
GrowBLOXTM suite of cultivation and growing chambers. To learn more
about Growblox Sciences, Inc., go to www.gbsciences.com.
Forward-Looking Statements: This press release
may contain statements relating to future results or events, which
are forward-looking statements. Words such as "expects",
"intends", "plans", "may", "could", "should", "anticipates",
"likely", "believes" and words of similar import may identify
forward-looking statements. These statements are not historical
facts, but instead represent only the Company's belief regarding
future events, many of which, by their nature, are inherently
uncertain and outside of the Company's control. It is possible
that the Company's actual results and financial condition may
differ, possibly materially, from the anticipated results and
financial condition indicated in these forward-looking
statements. Further, information concerning the Company and
its business, including factors that potentially could materially
affect the Company's business and financial and other results, are
contained in the Company's filings with the Securities and Exchange
Commission, available at www.sec.gov. All forward-looking
statements included in this press release are made only as of the
date of this press release, and we do not undertake any obligation
to publicly update or correct any forward-looking statements to
reflect events or circumstances that subsequently occur or of which
we hereafter become aware.
Note: Although the
Company's research and development activities are not illegal, the
production and sale of cannabis products violate federal laws as
presently constituted.
CONTACT: Growblox Sciences, Inc.
Cathryn Kennedy
702-576-5704
Cathryn@gbsciences.com
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Feb 2024 to Mar 2024
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Mar 2023 to Mar 2024